NRx Pharmaceuticals Launches First Commercial Manufacturing of Preservative-Free Ketamine
NRx Pharmaceuticals initiates first commercial manufacturing order of preservative-free ketamine ahead of potential GDUFA approval in summer 2026, backed by stability data and successful audit.
This development is crucial because it brings a potential new treatment option for suicidal depression and chronic pain closer to market. Preservative-free ketamine could offer a safer, more effective alternative for patients who have not responded to traditional therapies, addressing a significant gap in mental health care.
